Author

Tal Zvida

Observed names: Tal Zvida-Bloch, Tal Zvida‐Bloch

Institution: Ariel University

Observed institutions: Assuta Medical Center, Ariel University

ORCID: 0000-0002-8641-7813

Observed ORCID: 0000-0002-8641-7813

OpenAlex ID: A5082436054

The molecular landscape of AL amyloidosis

2025 · Tal Zvida‐Bloch, Eli Muchtar, et al. · British Journal of Haematology · 13

AL amyloidosis clonal plasma cells are regulated by microRNAs and dependent on anti‐apoptotic BCL2 family members

2023 · Hila Fishov, Eli Muchtar, et al. · Cancer Medicine · 9

The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms

2024 · Mali Salmon-Divon, Refael Meyuchas, et al. · Leukemia · 5

Targeting the PI3K/AKT Pathway and Fatty Acid Synthase in AL Amyloidosis: Mechanistic Insights and Therapeutic Implications

2024 · Tal Zvida-Bloch, Eli Muchtar, et al. · Blood · 1

Non-Coding RNAs Regulate Novel Signaling Pathways in AL Amyloidosis That Are Targetable By BCL2, PI3K and MEK Inhibitors

2022 · Tal Zvida, Eli Muchtar, et al. · Blood · 1

Loss of miR-146a-5p contributes to ibrutinib resistance in mantle cell lymphoma

2026 · Olga Kersy, Nir Cohen, et al. · Blood Advances

MAPK pathway-driven metabolic-inflammatory axis in AL amyloidosis

2025 · Tal Zvida-Bloch, Eli Muchtar, et al. · Blood

Non-coding RNAs regulate novel signaling pathways in AL amyloidosis that are targetable by FDA approved drugs PA38 (#269)

2024 · Oshrat Hershkovitz-Rokah, Tal Zvida, et al.

Works count: 8

Citation count: 29

H-index: 3

I10-index: 1